Behavioral Health and the New 340B Compliance Scrutiny
In early 2024, HRSA auditors began asking a new question when reviewing hospital and FQHC patient eligibility files: “How are you validating the prescriber relationship for behavioral health drugs ordered via telepsychiatry?” That single line surprised more than a few covered entities. Telepsych vendors were e-prescribing antipsychotics and ADHD medications under hospital NPIs, yet auditors couldn’t find a care relationship in the record. The fallout? Six-figure disallowances in 340B savings.
Anyone tracking audit trends saw this coming. Behavioral health prescribing has surged since COVID, with some hospitals reporting 40% year-over-year growth in psychotropic utilization. These scripts emerge from hybrid models, telehealth, mobile crisis teams, collaborative care, where documentation often falls out of sync with HRSA’s patient definition. The statute hasn’t changed since 1992, but HRSA’s FY2025 audit focus makes their mindset clear: more scrutiny on psychiatric, MAT, and substance use treatment programs is coming.
Patient Definition Meets Behavioral Health Care Delivery
HRSA still enforces its 2015 patient definition guidance, outdated or not. A “patient” must have a continuing relationship with the covered entity, and the prescriber must be employed, contracted, or otherwise tied to the entity’s care responsibility. Simple enough for a hospital outpatient clinic. Far messier when a contracted psychiatrist logs in virtually from another state.
One Missouri FQHC found out the hard way in 2023. Their telebehavioral vendor issued Suboxone prescriptions through the FQHC’s EHR using its provider ID, but the prescriber wasn’t on the 340B list submitted to HRSA. Every one of those claims was flagged and ultimately rebilled at WAC pricing for six months. The problem wasn’t diversion, it was paper trail. No HRSA-defined link between prescriber and entity existed. And HRSA doesn’t accept after-the-fact fixes.
These days, sharp 340B administrators require every behavioral health prescriber, whether telepsychiatrist, collaborative care physician, or MAT provider, to sign a written services contract that cites 340B accountability. They file that contract alongside encounter records proving the clinic’s continuing role in care. If you can’t show both, HRSA calls it diversion. Appeals? Still on ice. The ADR process never thawed after the Novartis and Sanofi disputes. Don’t bank on it.
Billing Integrity: Split Claims, Carve-Ins, and Behavioral Formularies
Billing behavioral drugs under 340B rules is a minefield. While HRSA avoids payer billing details, the OIG does not. Its 2022 report found several states overpaying 340B Medicaid claims missing the required modifier, especially for psychotropics with rebate implications. If your organization treats Medicaid patients with long-acting injectables like Invega Sustenna or Vivitrol, ensure your accumulation logic perfectly segments Medicaid FFS, MCO, and commercial inventories.
Here’s the worst practice still out there: using one NDC for both 340B and WAC dispensing across all payers and assuming your TPA will carve out Medicaid flawlessly. That’s asking for an audit. With injectables running $1,200 to $1,800 per dose, a single duplicate rebate error can erase a year’s benefit. HRSA and state Medicaid agencies have quietly synced enforcement. Many states now require quarterly crosswalks linking TPAs, 340B identifiers, and billed claims. Fail that test and you’re labeled noncompliant, audit or no audit.
Behavioral health TPA setups often falter because program teams never map eligible service sites correctly. Outpatient behavioral clinics count. Inpatient detox units don’t. If your dispensing pharmacy doesn’t know that distinction, your accumulator’s wrong, so is your replenishment. Forget “site mapping” assurances from your vendor. Get finance, clinical leadership, and your TPA analyst in a room. Name every prescriber, location, and payer feeding 340B accumulation. Behavioral health doesn’t bend to cookie-cutter frameworks. Trust me on that one.
Covered Entity Coordination in a Hybrid Behavioral Health Model
Behavioral health integration breeds compliance gray zones. HRSA doesn’t govern care coordination itself, but when two covered entities share behavioral staff, say, an FQHC embeds a community mental health center psychiatrist, the prescription ownership question turns thorny. Who owns the order? Whose encounter note controls? Where’s the record? HRSA expects one auditable record documenting continuity of care. Two systems, two claims, and you’ve just built a diversion case for them.
Administrators are tightening controls through what they call “behavioral health 340B compacts.” These cross-entity agreements specify which organization accumulates which drugs, under whose 340B ID, and set rules on prescriber scope of work. It’s not written anywhere in the regulations. It’s just the only position that holds under audit. Without it, dual-covered entities risk violating 340B twice with a single prescription.
Take one children’s hospital I worked with. Their psychiatry fellows rotated between the hospital and a university clinic, both 340B participants. Depending on the day, fellows prescribed under one Epic profile or the other. HRSA flagged the overlap in seconds. Fixing it meant locking down prescriber IDs and reconfiguring Epic access to rotation schedules. Awkward, messy, necessary. Cheaper than refunding half a year’s savings on atypical antipsychotics.
Looking Ahead: Where HRSA Oversight Is Heading in 2025
Recent HRSA meetings made one thing plain: behavioral health oversight under 340B is expanding. Expect new case studies testing patient definition through telepsychiatry. The upcoming audit selection algorithm will likely target entities showing a spike in psychotropic claims without matching EHR encounters. Message sent, behavioral health can’t be tacked on as an afterthought.
Manufacturers aren’t sitting back either. Johnson & Johnson and Alkermes have already limited contract pharmacy 340B dispensing for selected behavioral agents, mirroring the Eli Lilly and AstraZeneca moves from 2020. Hospitals and FQHCs depending on contract pharmacies for psychotropics need to run the loss scenarios now. Some have seen margins crash by 60% after being funneled to direct-distribution. Renegotiate distributor terms today if you haven’t. “Restoration pathways” aren’t automatic, HRSA’s stance notwithstanding.
Oversight. Billing integrity. Multi-entity coordination. They all collide hardest in behavioral health. It’s the fastest-growing 340B sector, and the least compatible with a definition written when telemedicine meant fax. The defense hasn’t changed: precise documentation, clean billing segregation, solid written agreements. Behavioral health keeps evolving. HRSA’s checklist, not so much. And that’s where we are, for now.